Literature DB >> 20441519

Effectiveness of varicella vaccine in children infected with HIV.

Moeun Son1, Eugene D Shapiro, Philip LaRussa, Natalie Neu, David E Michalik, Michelle Meglin, Andrea Jurgrau, Wally Bitar, Marietta Vasquez, Patricia Flynn, Anne A Gershon.   

Abstract

Although varicella vaccine is given to clinically stable human immunodeficiency virus (HIV)-infected children, its effectiveness is unknown. We assessed its effectiveness by reviewing the medical records of closely monitored HIV-infected children, including those receiving highly active antiretroviral therapy (HAART) between 1989 and 2007. Varicella immunization and development of varicella or herpes zoster were noted. Effectiveness was calculated by subtracting from 1 the rate ratios for the incidence rates of varicella or herpes zoster in vaccinated versus unvaccinated children. The effectiveness of the vaccine was 82% (95% confidence interval [CI], 24%-99%; P = .01) against varicella and was 100% (95% CI, 67%-100%; P < .001) against herpes zoster. When the analysis was controlled for receipt of HAART, vaccination remained highly protective against herpes zoster.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20441519      PMCID: PMC2871955          DOI: 10.1086/652798

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children.

Authors:  Thanyawee Puthanakit; Peninnah Oberdorfer; Noppadon Akarathum; Pornphun Wannarit; Thira Sirisanthana; Virat Sirisanthana
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

2.  Immunization of HIV-infected children with varicella vaccine.

Authors:  M J Levin; A A Gershon; A Weinberg; S Blanchard; B Nowak; P Palumbo; C Y Chan
Journal:  J Pediatr       Date:  2001-08       Impact factor: 4.406

3.  Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection.

Authors:  A A Gershon; N Mervish; P LaRussa; S Steinberg; S H Lo; D Hodes; S Fikrig; V Bonagura; S Bakshi
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

4.  Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster.

Authors:  Jason J Chen; Zhenglun Zhu; Anne A Gershon; Michael D Gershon
Journal:  Cell       Date:  2004-12-29       Impact factor: 41.582

5.  Incidence of opportunistic and other infections in HIV-infected children in the HAART era.

Authors:  Philimon Gona; Russell B Van Dyke; Paige L Williams; Wayne M Dankner; Miriam C Chernoff; Sharon A Nachman; George R Seage
Journal:  JAMA       Date:  2006-07-19       Impact factor: 56.272

6.  Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.

Authors:  Nutthapong Tangsinmankong; Wasu Kamchaisatian; Jorge Lujan-Zilbermann; Cynthia L Brown; John W Sleasman; Patricia J Emmanuel
Journal:  J Allergy Clin Immunol       Date:  2004-04       Impact factor: 10.793

7.  Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.

Authors:  Myron J Levin; Jeffrey P Anderson; George R Seage; Paige L Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731

Review 8.  The safety profile of varicella vaccine: a 10-year review.

Authors:  Susan A Galea; Ann Sweet; Paul Beninger; Sharon P Steinberg; Philip S Larussa; Anne A Gershon; Robert G Sharrar
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

9.  Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Mona Marin; Dalya Güris; Sandra S Chaves; Scott Schmid; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2007-06-22

10.  Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006.

Authors:  Sarah M Wood; Samir S Shah; Andrew P Steenhoff; Richard M Rutstein
Journal:  Pediatrics       Date:  2007-12-17       Impact factor: 7.124

View more
  16 in total

Review 1.  Update on opportunistic infections in the era of effective antiretroviral therapy.

Authors:  Brian C Zanoni; Rajesh T Gandhi
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

Review 2.  Vaccination in HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Mark R Wallace
Journal:  AIDS Patient Care STDS       Date:  2014-07-16       Impact factor: 5.078

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).

Authors:  Joanne F Chou; Nancy A Kernan; Susan Prockop; Glenn Heller; Andromachi Scaradavou; Rachel Kobos; Molly A Knowles; Esperanza B Papadopoulos; Anne Casson; Catherine Copeland; Joanne Torok-Castanza; Nicole Zakak; Julianne Ruggiero; Trudy N Small
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-23       Impact factor: 5.742

5.  Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques.

Authors:  V Traina-Dorge; B Pahar; P Marx; P Kissinger; D Montefiori; Y Ou; W L Gray
Journal:  Vaccine       Date:  2010-07-21       Impact factor: 3.641

6.  Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.

Authors:  Jie Zhang; Fenglong Xie; Elizabeth Delzell; Lang Chen; Kevin L Winthrop; James D Lewis; Kenneth G Saag; John W Baddley; Jeffrey R Curtis
Journal:  JAMA       Date:  2012-07-04       Impact factor: 56.272

7.  Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection.

Authors:  Murli U Purswani; Brad Karalius; Tzy-Jyun Yao; D Scott Schmid; Sandra K Burchett; George K Siberry; Kunjal Patel; Russell B Van Dyke; Ram Yogev; Robert H Lurie; Ram Yogev; Margaret Ann Sanders; Kathleen Malee; Scott Hunter; William Shearer; Mary Paul; Norma Cooper; Lynnette Harris; Murli Purswani; Mahboobullah Baig; Anna Cintron; Ana Puga; Sandra Navarro; Patricia Garvie; James Blood; Sandra Burchett; Nancy Karthas; Betsy Kammerer; Andrew Wiznia; Marlene Burey; Molly Nozyce; Arry Dieudonne; Linda Bettica; Susan Adubato; Janet Chen; Maria Garcia Bulkley; Latreaca Ivey; Mitzie Grant; Katherine Knapp; Kim Allison; Megan Wilkins; Midnela Acevedo-Flores; Heida Rios; Vivian Olivera; Margarita Silio; Medea Jones; Patricia Sirois; Stephen Spector; Kim Norris; Sharon Nichols; Elizabeth McFarland; Alisa Katai; Jennifer Dunn; Suzanne Paul; Gwendolyn Scott; Patricia Bryan; Elizabeth Willen
Journal:  Clin Infect Dis       Date:  2015-09-18       Impact factor: 9.079

Review 8.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 9.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

10.  Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children.

Authors:  Steven R Nesheim; Felicia Hardnett; John T Wheeling; George K Siberry; Mary E Paul; Patricia Emmanuel; Beverly Bohannon; Kenneth Dominguez
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.